PATENT CLAIM ANALYSIS

Application Number: 15754133
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["514", "283000"]

Abstract:
A method for treating diarrhea induced by a chemotherapy agent by administering a carboxylesterase 2 (CES2) inhibitor, i.e., hesperetin, naringenin, or 2′,4′-dihydroxychalcone. Also disclosed is a method for treating cancer by administering a chemotherapy agent together with hesperetin, naringenin, or 2′,4′-dihydroxychalcone. Furthermore, a composition for treating cancer is provided, the composition containing a chemotherapy agent and hesperetin, naringenin, or 2′,4′-dihydroxychalcone.

Claim (Index 23):
The use of  claim 22 , wherein the camptothecin analogue is irinotecan, topotecan, 7-ethyl-10 hydroxycamptothecin (SN-38), liposomal encapsulated SN-38, polyethylene glycol-conjugated SN-38, PEG-polyglutamic acid micelle encapsulated SN-38, or PEG-cyclodextrin encapsulated SN-38.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 88.0
- Lexical Diversity: 2.08333
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15481090', '15190805', '15281453', '14844772', '14669611']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7205304009774015
- 35 USC 102 Novelty (BERT): 0.526703716695643
- Combined Prediction Score: 0.7011477325492257
- Mean Citation Score: 287.455742
- Max Citation Score: 298.97815
- Similarity Product: 198.070750480932

Labels:
- Claim Label 101: 0
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test